Omeros Corporation (OMER)

Omeros Corp. stock has experienced significant events, including a 187.35% increase over the last six months. Key events include the FDA approval and U.S. launch of YARTEMLEA for HSCT-TMA, the assignment of a permanent reimbursement J-code for YARTEMLEA, and a strategic transaction with Novo Nordisk for zaltenibart, which included a $240 million upfront payment. The company reported a net income of $86.5 million for Q4 2025, driven by the zaltenibart transaction. However, the stock decreased by 17.7% from January 1st, 2026, to May 9, 2026.

There is no indication of traditional demand seasonality for Omeros Corporation's products and services. Demand is typically driven by factors like disease prevalence, diagnosis rates, and established treatment protocols, rather than seasonal consumer patterns. Discussions of "OMER Seasonality" in financial analyses refer to seasonal patterns in the stock's returns, not the demand for its products.

Omeros Corporation is a biopharmaceutical company focused on discovering, developing, and commercializing small-molecule and protein therapeutics, addressing immunologic disorders, complement-mediated diseases, cancers, and addictive and compulsive disorders. Its major products include Omidria, used to maintain pupil size and reduce postoperative pain during cataract surgery. Narsoplimab (YARTEMLEA) is a MASP-2 inhibitor targeting the lectin pathway of complement, approved for HSCT-TMA and evaluated for IgA nephropathy and COVID-19. OMS1029 is a long-acting MASP-2 inhibitor in Phase I clinical trials. OMS906 inhibits MASP-3 and is in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. OMS527 is a PDE7 inhibitor in clinical development for cocaine use disorders. Preclinical programs include MASP-2 and MASP-3 small-molecule inhibitors, Adoptive T-Cell and Immunostimulator Combination Therapies, and Oncotoxins and Immunomodulators for various cancers.

Omeros Corporation is headquartered in Seattle, Washington, and maintains research and development facilities in the United States and Europe. Omidria is marketed in the United States through a partnership with Mallinckrodt Pharmaceuticals, with regulatory filings underway in selected international markets.

Omeros Corporation generally holds a positive reputation, driven by scientific advancements and recent corporate achievements. The company has a consensus rating of "Moderate Buy" from analysts. The FDA approval of YARTEMLEA and the strategic partnership with Novo Nordisk have positively impacted Omeros's reputation. Improved financial performance in Q4 2025 has also been viewed favorably.

Omeros Corp. has a mixed ownership structure. Institutional investors hold approximately 42.04% to 47.11% of the company's shares, with major holders including BlackRock, Inc. and Vanguard Group Inc. Retail investors hold a substantial portion, ranging from 53% to 76.69% of the company's stock. Insiders own approximately 3.75% to 5.03% of the company's stock, with CEO Gregory A. Demopulos being a significant individual shareholder.